Vermillion is engaged in the discovery, development and commercialization of diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for women. Co. concentrates its development of diagnostic tests for gynecologic disease, with an initial focus on ovarian cancer. Co.'s primary product, OVA1, is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at high risk of having a malignant ovarian tumor prior to planned surgery. Co.'s ASPiRA LABS engages in applying biomarker-based technologies to address needs in the management of gynecologic cancers and disease.

VRML — News

VRML — Price Chart